SUBSCRIBE
SUBSCRIBE

Merck & Co.

  • 2024 Best Places to Work
  • 2023 Best Places to Work
  • 2022 Best Places to Work
213 E Grand Ave, South San Francisco, CA
33 Avenue Louis Pasteur, Boston, MA
320 Bent St, Cambridge, MA
NEWS
Merck & Co.'s Alzheimer's Contender Wows in Human Clinical Trial
Business
Merck & Co. Takes Out Immuno-Oncology Startup in $603 Million Deal
September 6, 2017
 · 
2 min read
Incyte Discloses Promising New Data in Combo Drug Trial With Merck & Co.'s Keytruda
Drug Development
Incyte Discloses Promising New Data in Combo Drug Trial With Merck & Co.'s Keytruda
August 31, 2017
 · 
3 min read
What You Missed: Nippon Fine Chemical Formed Human Barricade to Stop FDA Employee
FDA
Heads Up Tesaro: AstraZeneca PLC, Merck & Co.'s Ovarian Cancer Drug Just Got Expanded Use From the FDA
August 18, 2017
 · 
3 min read
What You Need to Know About Merck & Co.'s Fearless CEO Ken Frazier
Business
What You Need to Know About Merck & Co.'s Fearless CEO Ken Frazier
August 15, 2017
 · 
3 min read
What You Need to Know About Merck & Co.'s Fearless CEO Ken Frazier
Business
Merck & Co. CEO Resigns From President Trump’s American Manufacturing Council by Tweet
August 14, 2017
 · 
3 min read
AstraZeneca PLC Offloads Remaining Anesthetics Portfolio in $766 Million Deal
Business
AstraZeneca PLC Seals a $8.5 Billion R&D Cancer Tie-Up With Merck & Co.
July 27, 2017
 · 
3 min read
Merck & Co.'s Alzheimer's Contender Wows in Human Clinical Trial
Drug Development
Merck & Co. Plans to File NDA for HIV Treatment Doravirine Based on Phase III Results
July 26, 2017
 · 
3 min read
Biotech Bay
The Startling History Behind Merck & Co.'s New Cancer Blockbuster
July 26, 2017
 · 
1 min read
Merck & Co.'s Alzheimer's Contender Wows in Human Clinical Trial
Drug Development
Merck & Co. Dealt Another Setback as Its Ace Keytruda Comes Up Short in Head and Neck Cancer Study
July 25, 2017
 · 
3 min read
Load More
JOBS
IN THE PRESS
Up to 10-Years of Follow-up Data Reaffirm Safety Profile of Investigational Cladribine Tablets
October 10, 2018
 · 
7 min read
Pharm Country
Merck’s Broad Oncology Pipeline to Be Highlighted at ESMO 2018 Congress
October 9, 2018
 · 
51 min read
Genetown
ImmunoGen to Present Initial Data from FORWARD II Expansion Cohort of Mirvetuximab Soravtansine in Combination with KEYTRUDA at ESMO
October 8, 2018
 · 
4 min read
Drug Development
Merck Announces Week 96 Data from Pivotal Phase 3 DRIVE-AHEAD Study Evaluating DELSTRIGO™ (doravirine / lamivudine / tenofovir disoproxil fumarate) for the Treatment of HIV-1 in Treatment-Naïve Patients
October 4, 2018
 · 
13 min read
Drug Development
Merck’s HIV Therapy DELSTRIGO™ (doravirine / lamivudine / tenofovir disoproxil fumarate) Meets Primary Efficacy Endpoint in Phase 3 DRIVE-SHIFT Study Evaluating Switch to DELSTRIGO from Other Antiretroviral Treatment Regimens
October 4, 2018
 · 
12 min read
Drug Development
Positive Interim Data on Birinapant in Combination With Keytruda®
October 4, 2018
 · 
5 min read
Business
Dragonfly Therapeutics Announces New Multi-Target Collaboration with Merck to Use Dragonfly’s Proprietary TriNKET™ Platform to Develop Novel Drug Candidates for Patients with Solid Tumors
October 1, 2018
 · 
1 min read
Pharm Country
Merck Announces “Safer Childbirth Cities” Initiative, Issues Call to Action to Reverse the Rise in U.S. Maternal Deaths
October 1, 2018
 · 
6 min read
Business
Merck Board Rescinds Mandatory CEO Retirement Policy
September 26, 2018
 · 
3 min read
Policy
Merck Receives Positive CHMP Opinion for DELSTRIGO™ (doravirine/lamivudine/tenofovir disoproxil fumarate) and PIFELTRO™ (doravirine) in the European Union for the Treatment of HIV-1 Infection
September 20, 2018
 · 
10 min read
Load More